Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of HAL-MPE1 in Peanut Allergy
NCT02163018Phase 1Completed
- Sponsor
- HAL Allergy Group
- Start
- Jun 2014
- Primary completion
- May 2015
- Modality
- Recombinant Proteins and Enzymes, Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in peanut allergy comparing HAL-MPE1 with Placebo (2 arms). Primary endpoint: Safety of a SCIT-treatment with HAL-MPE1 at 20 weeks. Started Jun 2014; status: completed.
02
Drugs
HAL-MPE1
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT02163018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02163018.